7 d. ago Biotech firm touts new AI drug discovery amid third Hong Kong IPO attempt

Biotechnology firm Insilico Medicine said its new drug for lung disease, designed with the help of artificial intelligence (AI), showed positive results in the latest clinical trials, as the company pushes for a public listing in Hong Kong. Insilico found that its new small-molecule drug candidate, rentosertib, designed with its AI platform Chemistry42, was “generally safe and potentially effective” for treating idiopathic pulmonary fibrosis (IPF), according to its phase 2A clinical trial...

Economics

8 d. ago US sanctions Philippine tech firm over ‘pig butchering’ romance scams

A Philippine tech company has been sanctioned by the United States for allegedly enabling online romance scams known as “pig butchering”, which US authorities say led to more than US$200 million in losses reported by victims linked to the company’s infrastructure. Funnull Technology Inc, a content delivery network provider based in Metro Manila’s upscale Bonifacio Global City (BGC) district, was sanctioned last week by the US Treasury Department, along with Chinese national Liu Lizhi, described...

Politics

3 w. ago ‘What if AI had eyes’: meet Chinese firm Xreal, Google’s partner in AR glasses project

Project Aura provides a big boost to Xreal’s credentials in the smart glasses arena, while widening its reach in the international market.

Politics

3 w. ago Chinese biotech firm secures US$6 billion Pfizer deal for cancer drug

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

Economics

3 w. ago Chinese biotech firm secures Pfizer deal despite trade tensions

Chinese drug maker 3SBio has licensed its new cancer drug to US pharmaceutical giant Pfizer in the largest deal ever for China’s biotech industry, underscoring the strong commercial Sino-US ties despite geopolitical headwinds. Based in Shenyang, capital of northeastern Liaoning province, 3SBio will receive a US$1.25 billion upfront payment for licensing its cancer drug SSGJ-707 exclusively to Pfizer, which will manufacture and commercialise the drug outside mainland China, the companies...

Economics

3 w. ago Huawei’s chip unit doubled revenue last year as firm gains China smartphone market share

HiSilicon recorded a surge in revenue in 2024, driven by strong sales of Huawei’s Pura 70 and Mate 70 handsets, according to Counterpoint Research.

Economics